aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
March 19, 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018
March 07, 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 07, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at Two Upcoming Investor Conferences in March
March 01, 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04, 2018 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
December 21, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference
December 07, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
November 27, 2017 08:00 ET
|
aTyr Pharma, Inc.
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference
November 21, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
November 14, 2017 16:05 ET
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma Announces Leadership Transition
November 01, 2017 16:05 ET
|
aTyr Pharma, Inc.
– Dr. John Mendlein Transitions from CEO to Non-Executive Board Member,Dr. Sanjay Shukla Appointed President and CEO – SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE),...